Gates warm on local patch for next pandemic
BRISBANE: A patch invented at the University of Queensland which promises to deliver vaccine six times more effectively than needles has become a favourite of the Bill and Melinda Gates Foundation, which has awarded its creators a $7.5 million grant.
The so-called “micro-patch” being commercialised by start-up Vaxxas, which has raised $50 million in equity including from local venture funds Brandon Capital Management and OneVentures, is about five years from reaching the shelves, so it can’t help with any vaccine for COVID-19.
However, it could help stem future disease outbreaks by being faster to deploy, says Vaxxas chief executive David Hoey.
Mr Hoey said trials showed that vaccine delivered through the patch, which has a surface with thousands of “micro-projections” just a quarter of a millimetre long, could produce six times the response from antibodies as the same amount of vaccine delivered into the bloodstream via needle and syringe, and more quickly.
“So if you can use one-sixth the vaccine to get the same results faster, you can get it made up and deployed far more quickly and, as we’re learning, speed is everything in a pandemic response,” Mr Hoey said.
Vaxxas’ trials had shown it was not the case that delivering a vaccine straight into the bloodstream via needle was most effective, Mr Hoey said.
“The skin actually has the most immune cells in it of any organ in the body, and we can get straight into the lymphatic system and lymph nodes from there.
“Pump the vaccine into the bloodstream and it’s basically going to wander around the body until it bumps into an immune cell, which can take it to the lymph node for processing. We’re trying to avoid the bloodstream altogether.”
The patch is also pandemic-friendly because, Vaxxas claims, the vaccine has remained stable in trials at a temperature of 40 degrees Celcius for a year, meaning there is no need for a cold supply chain.
“It helps avoid the need for people to congregate in a central place to get vaccinated,” Mr Hoey said.
Piquing the interest of the Bill & Melinda Gates Foundation was the patch’s suitability for the developing world, Mr Hoey said.
Apart from no need for a cold supply chain, the patches also require no medical skills to administer.
“In a study that the World Health Organisation did for us in Benin, Nepal and Vietnam, the instructions for administration were a cartoon,” Mr Hoey said.
The $7.5 million grant from the Gates foundation will fund a trial of Vaxxas’ patch to administer rubella and measles vaccinations. It will be conducted in Australia.






